The skin gateway
to the Immune System

What's New ?

July, 28 2014


DBV Technologies Reports Financial Results for the First Six Months of 2014

Bagneux, France, July 28, 2014 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), the developer of Viaskin®, today announced interim financial results for the first half of 2014. The full interim financial report (regulated information) is available on DBV’s website, within the Investor Relations section. The 2014 half-year financial statements were subject to a limited review by the Company’s statutory auditors More

Events

May, 14 2014


Investor Day - New York City USA

  • Wednesday May 21st, 2014
          at 8.30am (US Time)
                2.30pm (CET)

More

A revolutionary approach in allergy treatment

11 to 26 million people suffer from food allergy in Europe while at the global level, the estimate is 220 to 500 million people. 3 to 5% of Americans suffer from food allergies and the prevalence of peanut allergy in children has almost quadrupled from 1997 to 2008…

EPIT Method Video

Missing flash plugin. Please download the latest Adobe Flash Player:
Get Adobe Flash Player

A short animation film explaining how DBV uses the Epicutaneous Immunotherapy with its VIASKIN patch to desensitize allergic patients

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
France
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH www.ovh.com

Design : l’enchanteur www.lenchanteur.com

Contact